Replies to post #95487 on Elite Pharmaceuticals Inc (ELTP)

[BuddyGuise]

Old timer, I do not have the name of the company, but I do know:

We engaged the prominent consulting firm in the field of company and stock price valuation. These are consultants who
are viewed as authorities on the subject. They have written the leading textbooks on the subject and
they worked regularly with the investment community.
They conducted a thorough study with lengthy interviews and due diligence. And then they finally issued
a 30 page report which confirmed our opinion. The report shows a conservative valuation, a most likely
valuation and a best case valuation. And I can tell you the conservative valuation was $0.40, most likely
was $2.10 and the best case valuation was $2.75, all of these on a fully diluted basis.
So that’s $0.40, $2.10 and $2.75 and that’s not future value, that’s the present value today. Future value
will be more. Now these valuations are based on the Elite executing its’ strategic plan and we’re on
schedule as you can tell by our financials.
The creation of a sound commercial base is occurring as evidenced by the rapidly growing revenues and
our product development is continued and accelerated. You read the stockholder’s rights plan, you will
note that we used the most likely valuation the $2.10 number as the value assigned to the Series H
shares included in that plan.
Now the valuation was needed for the creation of the plan but more importantly $2.10 is what
independent experts in the field have calculated as the most likely value of our stock today. With such a
spread between the current price and the underlying value, having this stockholder’s rights plan is
invaluable.
Today based on our stock price rising from $0.10 to the current level, I think we drove past $0.40 today.
It’s clear that many of you know we’re not a $0.10 company. However we hear at Elite feel, we’re much
more than a $0.30 or even a $0.40 company as well.